Stock 301047 SINO BIOLOGICAL,INC.
Add to a list
To use this feature you must be a member
Log inSign up

Sino Biological,Inc.

Equities

301047

CNE100004Q23

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
70.95 CNY +1.57% Intraday chart for Sino Biological,Inc. +4.96% -13.90%
Apr. 24 Sino Biological,Inc. Proposes Final Cash Dividend for the Year 2023 CI
Apr. 23 Sino Biological,Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Sino Biological,Inc.

Sino Biological,Inc. Proposes Final Cash Dividend for the Year 2023 CI
Sino Biological,Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Sino Biological,Inc.'s Equity Buyback Plan announced on February 23, 2024. CI
Sino Biological,Inc. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 19, 2024. CI
Bio-Link Pharmaceutical Technology Co., Ltd. announced that it has received funding from Cathay Capital Private Equity SAS, Sino Biological,Inc., Suzhou GSL Venture Capital Management Company, Beijing GSR United Capital Management Consulting Co., Ltd., Tianjin Qianxi Investment Management Partnership Ent. (L.P.), Shanghai Pudong Haiwang Private Fund Management Co., Ltd. and other investors CI
Sino Biological,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Sino Biological to Acquire Canada’s SignalChem Biotech for $48 Million MT
Sino Biological,Inc. entered into Share Purchase Agreement to acquire SignalChem Biotech Inc. from Signalchem Lifesciences Corporation for CAD 65.85 ?million. CI
Sino Biological,Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Certain A Shares of Sino Biological Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2023. CI
Sino Biological Unit to Lease Beijing Property to Shenzhou Cell Engineering MT
Sino Biological Buys Land for 918 Million Yuan MT
Sino Biological,Inc Approves the Final Cash Dividend for the Year 2022, Payable on 24 May 2023 CI
Sino Biological,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sino Biological,Inc. Proposes Final Cash Dividend for the Year 2022 CI
Sino Biological,Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sino Biological,Inc. Approves Board Elections CI
PhaBuilder announced that it has received $53.4 million in funding from Sino Biological,Inc., Beijing Zhonghai Investment Management Co., Ltd., Shanghai Free Trade Zone Equity Fund Management Co., Ltd., Chengtong Fund Management Co., Ltd., CNPC Kunlun Capital Co., Ltd., Shanghai Lingang Innovation Center Co., Ltd. CI
Sino Biological to Form 1 Billion Yuan Industrial Investment Fund MT
Investors bet China's rally on easing COVID curbs will be furious but fleeting RE
ChiNext Announces Construction of Its New Us-Based Center for Bioprocessing CI
PhaBuilder announced that it expects to receive CNY 95 million in funding from Sino Biological,Inc., Lhasa Ailike Investment Consulting Co., Ltd CI
Sino Biological,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Sino Biological,Inc.(XSEC:301047) added to S&P Global BMI Index CI
Certain A Shares of Sino Biological Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2022. CI

Chart Sino Biological,Inc.

Chart Sino Biological,Inc.
More charts

Company Profile

Sino Biological Inc is a China-based biotechnology company engaged in the research and development, production, sales and technical services of biological reagents. The Company's main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services. The Company operates in the domestic market and overseas markets.
Sector
Biotechnology & Medical Research
Calendar
2024-04-28 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biological,Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
70.95 CNY
Average target price
102.5 CNY
Spread / Average Target
+44.47%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SINO BIOLOGICAL,INC. Stock Sino Biological,Inc.
-13.90% 1.27B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 301047 Stock
  4. News Sino Biological,Inc.
  5. Sino Biological to Acquire Canada’s SignalChem Biotech for $48 Million